It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study aimed to explore the potential of metal oxides such as Titanate Scrolled Nanosheets (TNs) in improving the radiosensitivity of sarcoma cell lines. Enhancing the response of cancer cells to radiation therapy is crucial, and one promising approach involves utilizing metal oxide nanoparticles. We focused on the impact of exposing two human sarcoma cell lines to both TNs and ionizing radiation (IR). Our research was prompted by previous in vitro toxicity assessments, revealing a correlation between TNs' toxicity and alterations in intracellular calcium homeostasis. A hydrothermal process using titanium dioxide powder in an alkaline solution produced the TNs. Our study quantified the intracellular content of TNs and analyzed their impact on radiation-induced responses. This assessment encompassed PIXE analysis, cell proliferation, and transcriptomic analysis. We observed that sarcoma cells internalized TNs, causing alterations in intracellular calcium homeostasis. We also found that irradiation influence intracellular calcium levels. Transcriptomic analysis revealed marked disparities in the gene expression patterns between the two sarcoma cell lines, suggesting a potential cell-line-dependent nano-sensitization to IR. These results significantly advance our comprehension of the interplay between TNs, IR, and cancer cells, promising potential enhancement of radiation therapy efficiency.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Bordeaux, UMR 5797, LP2I Bordeaux, CNRS, Gradignan, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X); University of Bordeaux, U1212, IECB, INSERM, Pessac, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X)
2 University of Bordeaux, UMR 5797, LP2I Bordeaux, CNRS, Gradignan, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X); Institut Bergonié, Radiation Oncology Unit, Bordeaux, France (GRID:grid.476460.7) (ISNI:0000 0004 0639 0505)
3 University of Bordeaux, UMR 5797, LP2I Bordeaux, CNRS, Gradignan, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X)
4 University of Bordeaux, UMR 5026, ICMCB, Bordeaux INP, CNRS, Pessac, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X)
5 Institut Bergonié, Radiation Oncology Unit, Bordeaux, France (GRID:grid.476460.7) (ISNI:0000 0004 0639 0505)
6 University of Bordeaux, U1212, IECB, INSERM, Pessac, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X)